The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Silvia Pieralice,1 Rocco Amendolara,1 Valentina Berna,1 Giuseppina Manganaro,2 Annalisa Zurru,1 Luca D’Onofrio,1 Renata Risi,1 Marianna Alfonsi,1 Ernesto Maddaloni,1 Raffaella Buzzetti1 1Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy; 2Vita- Salute San Raffaele Univers...
Saved in:
| Main Authors: | Pieralice S, Amendolara R, Berna V, Manganaro G, Zurru A, D'Onofrio L, Risi R, Alfonsi M, Maddaloni E, Buzzetti R |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-07-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-emerging-role-of-anti-hyperglycemic-agents-for-the-management-of-m-peer-reviewed-fulltext-article-DMSO |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver diseaseKeypoints
by: Robert F. Schwabe, et al.
Published: (2025-08-01) -
A systematic review and meta-analysis of efruxifermin’s efficacy in improving liver fibrosis in patients with NASH/MASH
by: Shuzhai Li, et al.
Published: (2025-05-01) -
Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose
by: Satoshi Shinozaki, et al.
Published: (2025-02-01) -
A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
by: Jeffrey V. Lazarus, et al.
Published: (2025-01-01) -
Body Composition and Progression of Biopsy‐Proven Non‐Alcoholic Fatty Liver Disease in Patients With Obesity
by: Qianyi Wan, et al.
Published: (2024-12-01)